Naxitamab (Danyelza)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: glycolipid GD2 recombinant humanized monoclonal IgG1 antibody. Naxitamab-gqgk binds to the glycolipid GD2, which is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, binding resulted in complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Generic name: naxitamab-gqgk
  • Brand name: Danyelza

References